Clinical Trial: French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables: •Withdrawal of previous cytoreductive therapy: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables: •Withdrawal of previous cytoreductive therapy:
Original Primary Outcome: To determine how different treatment regimens, during the initiation of XAGRID into a patient's essential thrombocythemia (ET) therapy, affect continuation with treatment in the first 6 months. [ Time Frame: 6 months ]
Current Secondary Outcome: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables: •Withdrawal of previous cytoreductive therapy: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables: •Withdrawal of previous cytoreductive therapy: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables: •Withdrawal of previous cytoreductive therapy: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when XAGRID treatment was initiated, using the following variables: Consistent if: Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when XAGRID treatment was initiated, using the following variables: Consistent if:
Original Secondary Outcome:
Dates:
Information By: Shire
Date Received: August 26, 2010
Date Started: September 2010
Date Completion:
Last Updated: February 14, 2014
Last Verified: February 2014